embecta-sponsored educational symposium and ATTD abstract highlights the role of insulin pumps in the management of type 2 diabetes

PARSIPPANY, N.J., March 6, 2024 (GLOBE NEWSWIRE) — Envector Corporation (“Envector”) (Nasdaq: EMBC), a global diabetes care company with a 100-year heritage in insulin delivery, announced today that announced the support of At the International Conference on Advanced Technologies and Therapies for Diabetes (ATTD). This event is scheduled for Wednesday, March 6th at 10:40 AM ET / 14:40 CET. In addition, six of his embecta-sponsored abstracts focused on injectable and insulin pump therapy were selected for presentation as scientific posters at ATTD 2024.

The symposium, entitled “Unlocking the Potential of Insulin Pumps for Personalized T2D Care,” highlighted the importance of insulin pump therapy among the wide range of treatment options available for type 2 diabetes (T2D). It is intended to emphasize. Through a series of presentations and panel discussions by distinguished faculty, attendees will gain insight into the clinical considerations for initiating insulin pump therapy, including choosing the optimal pump.

“We are thrilled to support this symposium as part of our ongoing efforts to foster innovation and improve care for people with type 2 diabetes,” said Henry Anhalt, M.D., chief medical officer at embecta. Ta. “Enhancing informed decision-making regarding patient insulin pump therapy”

The symposium will be chaired by Natalie J. Bellini, DNP, FNP-BC, BC-ADM, CDCES, Clinical Assistant Professor of Medicine at Case Western Reserve University. She will be joined by Virus N. Shah, MD, PhD, professor of medicine in the Division of Endocrinology and Metabolism at the Indiana University School of Medicine and director of diabetes clinical research in the IU Center for Diabetes and Metabolic Disease, and Stephen V. Edelman, MD, University of California, San Diego. Professor of Medicine at the Veterans Affairs Medical Center and founder and director of Taking Control Of Your Diabebet. This gathering of experts highlights embecta’s commitment to leading diabetes care through education, innovation, and support of impactful research.

story continues

The six embecta-sponsored abstracts, set to be presented as scientific posters, contain solid data on insulin therapy, both by pump and multiple daily injections (MDI). For example, one poster by Dr. Shah et al. found that type 2 diabetic patients receiving MDIs used an average daily total dose of 95.9 units of insulin. Another poster highlights data showing that insulin pump therapy alleviates the limitations of diabetes management and improves quality of life in patients with type 2 diabetes.

“Dr. Shah and his co-authors’ research findings support insights gained by the Envector team through our close collaboration with people living with type 2 diabetes and their health care providers,” said Anhalt. . “A larger He pump with a 300-unit insulin reservoir can meet a critical unmet need, allowing an adult with type 2 diabetes to save her three with one pump.” You may be able to manage your symptoms over a period of days.”

The titles and authors of the poster presentations sponsored by embecta are as follows:

• Multiple daily insulin administration (MDI) in US adults with type 2 diabetes (T2D): a retrospective cohort study — Lead author: Dr. Viral Shah

• Obesity and disparities in glycemic outcomes are prevalent among adults with type 2 diabetes undergoing MDI: a large retrospective cohort study in the United States — Lead author: Dr. Eugene Wright

• Knowledge and attitudes regarding insulin pump use among adults with type 2 diabetes in the United States. — First author: Dr. Bill Polonsky

• Primary care physicians’ perspectives on insulin pump use for patients with type 1 and type 2 diabetes in the United States. — First author: Dr. Steve Edelman

• Relationship between lipohypertrophy, glycemic control, and insulin administration: a systematic meta-analysis – EMEA region – First author: Dr. Julia Mader

• Needlestick injuries from insulin injections: risk factors, concerns, and impact of safety pen needle use in the Asia-Pacific region — First author: Dr. Mafawzi Mohamed

ATTD 2024 will be held from March 6th to 9th, 2024 at Forte Basso in Florence, Italy, and can be accessed virtually.

About envectors
embecta is a global diabetes care company that leverages a 100-year heritage in insulin delivery to help people with diabetes live their best lives through innovative solutions, partnerships and the passion of more than 2,000 employees worldwide. It’s a company. For more information, please visit: envector.com Or follow us on our social channels linkedin, Facebook, Instagram and twitter.